Clay Siegall: Changing the World Through Innovation

Seattle Genetics is poised to make a big impact in the world of biotechnology. Under the leadership of dedicated Chairman, President, CEO, and co-founder Clay Siegall, the company is working harder than ever to make the switch from a moderately sized biotech company to the world of big pharma. Siegall explains that he modeled the business strategy of the famed entrepreneur Art Levison and his work with Genentech in the early development of Seattle Genetics. He hopes to mimic important aspects of Levison’s business plan to bolster his already successful pharmaceutical company. To accomplish this goal, Siegall has Seattle Genetics pointed in a very specific direction with the development of several new drugs with big treatment goals. One major field of medicine that Seattle Genetics has taken interest in is oncology. In a recent article with Seattlebusinessmag.com, Siegel discusses the implications these drugs will have in the medical community after their successful testing. While Seattle Genetics is currently working on the release of 11 pharmaceuticals, Siegall is specifically interested in the success of four. These four are Adcetris, 33A, 22ME. And LIV1. Each drug has been created to target specific cancer, and Siegall is confident that they will hit the market with stunning medical implications for those who may stand to benefit from them.

Prior to co-founding Seattle Genetics in 1998, Siegall obtained a Ph.D. in Genetics from George Washington University. He eventually used his degree to obtain a job with the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, and The National Institute of Health. While each of these jobs represented a major time in Siegall’s knowledge development, they were also stepping stones to his eventual development of Seattle Genetics.

Currently, Siegall is still serving as the company’s Chairman, CEO, and president. In 2001, Siegall spearheaded a funding raising campaign in which Seattle Genetics went to a public offering company. This event generated over $675 million in revenue and contributed to the significant development of the company. In addition to his duties with Seattle Genetics, Siegall is also a sitting member of the Board of Directors for Alder BioPharmaceuticals. While Siegall seems to have everything he might need professionally, he has made it clear that Seattle Genetics is always going to be pushing forward in the biotech industry. His hard work and dedication have helped push the company into the top tier of its field. As Siegel leads Seattle Genetics into the future, there is no doubt they are only just beginning to change the world.

Leave a Reply

Your email address will not be published. Required fields are marked *